OTCPK:EQUR

Stock Analysis Report

Executive Summary

E-Qure Corp., a medical device company, focuses on the development and commercialization of bioelectrical signal therapy (BST) devices.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has E-Qure's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EQUR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

EQUR

10.2%

US Medical Equipment

9.4%

US Market


1 Year Return

-60.5%

EQUR

2.1%

US Medical Equipment

-6.8%

US Market

Return vs Industry: EQUR underperformed the US Medical Equipment industry which returned -1.6% over the past year.

Return vs Market: EQUR underperformed the US Market which returned -10% over the past year.


Shareholder returns

EQURIndustryMarket
7 Day0%10.2%9.4%
30 Day-62.5%0.9%-3.9%
90 Day-66.7%-12.1%-16.5%
1 Year-60.5%-60.5%2.9%2.1%-4.8%-6.8%
3 Year-85.0%-85.0%57.1%52.9%23.4%15.2%
5 Year-93.2%-93.2%89.2%69.8%41.3%25.7%

Price Volatility Vs. Market

How volatile is E-Qure's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is E-Qure undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether E-Qure is trading at an attractive price based on the cash flow it is expected to produce in the future. But as E-Qure has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of EQUR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through E-Qure regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is E-Qure forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as E-Qure has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of EQUR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access E-Qure's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has E-Qure performed over the past 5 years?

71.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EQUR is currently unprofitable.

Growing Profit Margin: EQUR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EQUR is unprofitable, but has reduced losses over the past 5 years at a rate of 71.1% per year.

Accelerating Growth: Unable to compare EQUR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EQUR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.4%).


Return on Equity

High ROE: EQUR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is E-Qure's financial position?


Financial Position Analysis

Short Term Liabilities: EQUR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: EQUR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: EQUR has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: EQUR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EQUR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: EQUR has less than a year of cash runway if free cash flow continues to reduce at historical rates of -17.8% each year


Next Steps

Dividend

What is E-Qure's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EQUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EQUR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EQUR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EQUR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EQUR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Ohad Goren (48yo)

5.83s

Tenure

Mr. Ohad Goren has been the Chief Executive Officer of E-Qure Corp. since June 2014 and its Director since July 25, 2018. Mr. Goren has been an Advisor and Entrepreneur to Medical Device companies since 20 ...


CEO Compensation Analysis

Compensation vs Market: Ohad's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD615.59K).

Compensation vs Earnings: Insufficient data to compare Ohad's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Ohad Goren
CEO & Director5.83yrsno data4.49% $46.5k
Gal Peleg
Chief Financial Officer5.67yrsno data0.65% $6.7k
Itsik Ben Yesha
CTO & Director1.75yrsUS$72.50k12.63% $130.9k
Itai Weisberg
Chief Marketing Consultant6.75yrsno datano data

5.8yrs

Average Tenure

48yo

Average Age

Experienced Management: EQUR's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ohad Goren
CEO & Director5.83yrsno data4.49% $46.5k
Itsik Ben Yesha
CTO & Director1.75yrsUS$72.50k12.63% $130.9k
Ben-Zion Weiner
Member of Advisory Boardno datano datano data
Michael Sessler
Independent Director5.67yrsno datano data
Avi Ohry
Member of Advisory Boardno datano datano data
Ron Weissberg
Chairman6.33yrsno data12.37% $128.2k

3.7yrs

Average Tenure

60yo

Average Age

Experienced Board: EQUR's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.6%.


Top Shareholders

Company Information

E-Qure Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: E-Qure Corp.
  • Ticker: EQUR
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.036m
  • Shares outstanding: 34.55m
  • Website: https://www.e-qure.com

Number of Employees


Location

  • E-Qure Corp.
  • 20 West 64th Street
  • Suite 39G
  • New York
  • New York
  • 10023
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EQUROTCPK (Pink Sheets LLC)YesCommon StockUSUSDApr 1989

Biography

E-Qure Corp., a medical device company, focuses on the development and commercialization of bioelectrical signal therapy (BST) devices. Its BST devices implement patented and proprietary electrical stimulation technologies to treat hard-to-cure wounds and ulcers down to complete closure and/or cure. E-Qure Corp. is based in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/09 00:21
End of Day Share Price2020/03/23 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.